Estimating cancer risk from space radiation has been an ongoing challenge for decades primarily because most of the reported epidemiological data on radiation-induced risks are derived from studies of atomic bomb survivors who were exposed to an acute dose of gamma rays instead of chronic high-LET cosmic radiation. In this study, we introduce a formalism using cellular automata to model the long-term effects of ionizing radiation in human breast for different radiation qualities. We first validated and tuned parameters for an automata-based two-stage clonal expansion model simulating the age dependence of spontaneous breast cancer incidence in an unexposed U.S. population. We then tested the impact of radiation perturbation in the model by modifying parameters to reflect both targeted and nontargeted radiation effects. Targeted effects (TE) reflect the immediate impact of radiation on a cell's DNA with classic end points being gene mutations and cell death. They are well known and are directly derived from experimental data. In contrast, nontargeted effects (NTE) are persistent and affect both damaged and undamaged cells, are nonlinear with dose and are not well characterized in the literature. In this study, we introduced TE in our model and compared predictions against epidemiologic data of the atomic bomb survivor cohort. TE alone are not sufficient for inducing enough cancer. NTE independent of dose and lasting ;100 days postirradiation need to be added to accurately predict dose dependence of breast cancer induced by gamma rays. Finally, by integrating experimental relative biological effectiveness (RBE) for TE and keeping NTE (i.e., radiation-induced genomic instability) constant with dose and LET, the model predicts that RBE for breast cancer induced by cosmic radiation would be maximum at 220 keV/lm. This approach lays the groundwork for further investigation into the impact of chronic low-dose exposure, inter-individual variation and more complex space radiation scenarios.
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INTRODUCTION
While space programs have recently shifted to planetary exploration, in particular missions to the moon and Mars, continuous exposure of astronauts to galactic cosmic rays (GCR) is a main concern in long-term missions because of increased risk of cancer and other degenerative diseases. The GCR spectra contains a large component of high-linear energy transfer (LET) particles, such as helium ions and heavier ions such as carbon and iron [high-energy charged (HZE) particles] (1). Despite the low frequency of GCR, they are a major contributor to cancer risk because of their high ionization density, which can lead to severe mutational events. It has been reported that high-LET ionizing radiation induces a relative biological effectiveness (RBE) of up to 40 in animal models (2) . Also of concern are solar particle events (SPE) (3) that have an unpredictable nature and at high doses, pose a risk for out-of-spacecraft tasks.
Unfortunately, estimating cancer risk from space radiation remains a challenge primarily because most epidemiological data showing evidence of cancer risk from ionizing radiation are derived from studies of atomic bomb (Abomb) survivors (4) . Classic risk models rely on scaling variables, such as radiation-quality factor Q, RBE and dose and dose-rate effectiveness factor to extrapolate risk from gamma radiation (main radiation in A-bomb blast) to high-LET radiation in space.
This poses the question of whether risk estimates derived from sparsely ionizing radiation can be used to assess risks associated with HZE. In this work, we introduce a formalism using cellular automata to test mechanisms that can reproduce cancer incidence by modeling the short-term and long-term effects of ionizing radiation in tissue. Cellular automata are stochastic models where each cell is represented by an algorithmic entity with basic individual properties representing the variety of cellular behaviors (5, 6) . We first established a relationship between gamma radiation dose and cell death, cell senescence and genomic instability for various time scales. This relationship was tuned so that we could accurately predict breast cancer incidence in humans (A-bomb cohort vs. unexposed population). In a second phase, the model was used to test new mechanisms of DNA misrepair and cell death from high-LET radiation (7) to predict high-LET response and RBE for various cosmic radiations. This model is the first step in addressing the growing demand for more in-depth information about the biological processes underlying carcinogenesis and their disruption by heavy ions (1).
MATERIALS AND METHODS

Multistage Expansion Model: Theoretical Considerations
We focused on the concept of the multistage expansion model, which provides an analytical solution to epidemiological cancer incidence (8) . This model assumes that malignant tumors arise from a series of modifications of a single progenitor cell and that cancer is the last of a series of k sudden and irreversible changes. For a cell that has already undergone (i-1) changes, the event rate for the next change is l i . The exact solution can be derived from Bateman's solution of successive radioactive decays and the stage p m-1 (t) can be expressed as:
with c m ¼ aP mÀ1 j ¼1 l jÀ1;j and X j,m ¼ P
with N as the total number of affected cells. The first nonvanishing term in a Taylor series of p k-1 (t) gives the wellknown Armitage-Doll model (9) :
However, this simpler model gives a power law for the agedependent incidence and it is known that the cancer incidence flattens above age 60 and falls below the predicted curve. Pompei and Wilson proposed a modified version of this model by adding a senescence factor and assuming that malignant cells are mortal in the sense of Hayflick (i.e., cell divisions are not infinite) (10) . If a malignant cell is completely senescent, this cell does not produce observable cancer. The hazard function better fits the epidemiological data at high age (11) and takes the following form:
However, not all the initiated cells can progress to cancer as some of them can be repaired or removed. This leads to a more refined model involving only two stages (k ¼ 0,1,2) and a death rate for intermediate cells (12, 13) . The Moolgavkar, Venzon and Knudson (MVK) model or two-stage clonal expansion (TSCE) model gives then a hazard of the form:
where X m , c and q can be related to actual biological parameters using the following transformations:
Here, m is the proportion of healthy cells that will acquire a first mutation, l 2 is the rate of the second mutation, a and b are growth and death or differentiation rate for intermediate cells, respectively. This model can be thought of as the initiation-promotion-progression paradigm of carcinogenesis.
Nonexposed Tissue
Tissue description. Because deterministic models are not well suited to simulate heterogeneous tissue and as our laboratory is establishing a long-term computer framework for more complex radiation simulations, we use instead automata to simulate cancer incidence via the principle of TSCE. An important reason for this choice is that it is easy to add new rules or different geometrical configurations in automata, making them an ideal framework for evolving simulations.
Simulations were performed using MATLABt software (MathWorkst, Natick, MA) and the advanced imaging platform DIPimage (Image Processing Toolbox for Matlab, Delft University of Technology, Delft, The Netherlands). The simulated tissue consists of an array of 100 3 100 pixels, with each pixel labeled with a particular stage. Figure 1A depicts conceptually the progression of a normal cell via successive mutations towards becoming a tumor cell, highlighting the importance of tissue proliferation for cancer to occur. The automata implementation of this progression is shown in Fig. 1B with a flow chart showing decision algorithms. Stage 1 (green pixel) represents a normal cell; stage 2 (blue pixel) is a cell harboring a potentially dangerous mutation in the context of cancer induction (i.e. initiated); and stage 3 (red pixel) is a cell harboring the two necessary mutations to expand into a full-blown cancer. Fig. 1C shows snapshots of one simulation where tissue is progressing towards cancer over many years.
With the TSCE assumption, cell death is a necessary condition for neighboring cells to divide and potentially acquire mutations. The automata approach assumes additionally that the tissue is in homeostasis, which means that dead cells are rapidly replaced by newly dividing cells. Consequently, division and death rate are identical (a ¼ b). It can be noted in Fig. 1B that all cells touching a dying cell are eligible to fill the gap that is left behind. The selection of which neighboring cell will fill the gap is drawn randomly. Thus, whenever a cell divides, the new cell filling this gap has an opportunity to acquire a mutation related to carcinogenesis. In a general implementation of this model, if the mother cell carries n mutations, there is a probability that the daughter cell will carry n þ 1 mutations. A cell harboring a lot of mutations is likely to be more unstable genetically. Because there is no clear law defining the relationship between progression and genomic instability, for now we are imposing a mutation rate proportional to the cell stage. This assumption allows us to reduce the number of mutation parameters to only one value: i.e., l, the spontaneous mutation rate in a healthy cell. Note that both stage 2 and 3 can be reached by way of various unique combinations of genes being mutated, but details on genetic changes that lead to this pre-cancer state are not necessary in this model, as it is fully encompassed by determining l. The mutation model can be summarized as:
In this approach, division is therefore driven by the turnover of the tissue being simulated. In the case of breast tissue, it has been shown that the cell death rate b is periodic due to the menstrual cycle of estrogen and progesterone. Rising progesterone levels drive mammary cells in ducts and alveoli to multiply for possible pregnancy. If there is no pregnancy, progesterone levels drop and induce cell death of newly formed tissue. If we assume a 28-day cycle with an apoptotic peak between days 28 and 0, the death rate pattern for different ages can be modeled ( Fig. 2A) . The amplitude and average values used here are derived from the literature and they are lower with increasing age (14-16) with a rate b in the order of 10
À3
/day/cell. At menopause, the death rate is considered flat and lower than the premenopausal value (17) . For each simulated person, the age at menopause for an in silico individual is established based on a triple Gaussian distribution (centers: 50.3, 42.9 and 35.3 years old) as previously suggested (18) , leading to a smooth drop of cell death in simulations, as shown in Fig.  2B . Note that parameters for normal cell turnover in the breast are not changed for the rest of this model since they are directly derived from the literature.
Senescence. Senescent cells were also considered in this model. They are represented as pixels that are unable to divide or die (i.e., stage À1). In other words, senescent pixels no longer divide and have acquired resistance to apoptotic signals. Our senescence model takes into account the age of the tissue being simulated. Telomere-initiated cellular senescence is also included in the model by generating senescence in only dividing cells. Briefly, at each time step, a random number is generated for each stage 1 and stage 2 pixel. This number is compared to the senescence probability, which changes as the square of the age of the tissue (19) :
If the random number is less than p senescence , the cell is set to stage À1. Running a parameter sweep on the senescence factor sen factor , a value of 5 3 10
À9
/day led to a curve matching the literature for primates (19) (Fig. 2C ). In addition, a baseline of 2% senescence was imposed on the tissue at the starting age of 20 years to reflect the primate data. Note that compared to primates, the age scale has been expanded to reflect the human life span. We also assumed that stage 3 pixels (cancer cells) cannot senesce anymore since they have acquired mutations that allow them to avoid telomere-dependent and oncogenedependent senescence (20) .
Parameter calibration to match breast cancer data. Key parameters in the TSCE model are the mutation rates: i.e., initiation (with probability l 1 ¼ l) and transformation (l 2 ¼ 2l). Because of our assumption about increase of genomic instability with progression, we only needed to determine l. It turns out that cancer incidence frequencies are not only dependent on l but also on the size of the tissue being simulated. To understand this relationship, we performed a parameter sweep on l for a different number of cells considered in each modeled duct, and determined values of l that led to simulations matching published spontaneous cancer incidence. Note that agespecific SEER breast cancer incidence rates were taken from SEER Cancer Registry records 2008-2012 (21) . Figure 2D shows simulated cumulated cancer incidence predicted by the model for various initial tissue sizes being considered against SEER records (diamonds and dashed line for fit). Simulations were repeated 10 times with a group of 50 in silico people and parameter sweep on l was conducted to lead to the lowest mean square error between prediction and published data. We show that simulations fit very accurately to epidemiologic data for various tissue sizes as long as the mutation rate was adjusted consequently, noting that the larger the number of cells being simulated in the tissue, the lower l needs to be. This relationship was well behaved, with a power dependence of l versus the number of cells being simulated (R 2 . 0.999, data not shown). Ideally, one would like to simulate tissue of realistic sizes, however, this would be extremely time consuming for simulations and our data suggest as long as l is set accordingly with the tissue size, the model behaves correctly. We therefore used going forward for our radiation prediction an initial tissue size of 100 3 100, leading to a l value of 3.8 3 10
À6 . Each individual was simulated as a branch of a mammary duct made of 10,000 cells (22) .
Parameters having the greatest impact on the final curve are l and b. Cell death rate b is defined by the menstrual cycle for normal cells only (stage 1), which represents the majority of the cells at the beginning of simulation (age 20) and is fixed by experimental data ( Fig. 2A) . On the other hand, once a cell has become mutated, it becomes hormone independent and cell death is only driven by genetic instability, which increases with progression (see Fig. 1A ). For example, high-grade tumors have higher levels of apoptosis and genomic instability, which is usually correlated with poor prognosis (23) (24) (25) . A parameter sweep was performed on the b value for stages 2 and 3 to best fit experimental incidence, and values are summarized in Table 1 , confirming that b needs to increase with progression to get accurate cancer prediction.
Note that during parameter sweep, increasing either l or b 2 and b 3 led to higher cancer incidence and thus multiple solutions for the same final cumulated incidence at age 80. However, a single solution was obtained by minimizing the error along the full age dependence between the published data and the simulations. This was done by finely tuning b 2 and b 3 down while increasing l. Note that a cancer growth factor is also present in the model and was based on the assumption that it takes 20 years between an initiating event and a detectable cancer. The growth factor is a metric representing the ability of neoplastic cells (stage 3) to grow and expand over neighboring healthy cells. After a set number of iterations, all stage 3 cells take over their immediate neighbors. This process reflects the loss of contact inhibition in cancer cells and loss of checkpoints regulating mitosis. The tumor growth parameter was set to once a year for breast cancer. It is easily tunable to model other types of more aggressive cancers and is relatively arbitrary since a cancer is scored in our model once 5% of the tissue has become stage 3.
Impact of senescence on cancer incidence. We investigated the hypothesis that senescent cells can slow down cancer progression. The senescence response is widely recognized as a potent tumor suppressive mechanism (26) (27) (28) . The senescent factor parameter was thus increased to reach various levels of senescence at age 80 and the
FIG. 2.
Model calibration on spontaneous breast cancer incidence. Panel A: The death rate, b, is set periodic to match the menstrual cycle, with an amplitude and baseline that decreases with age until reaching menopause, where rate stabilizes at 0.4e-3 per day. Panel B: Average number of dying cells as tissue ages in silico. Panel C: Simulation of the percentage of senescent cells in the tissue compared to published data for primate (19) . Best fit is obtained for a senescence factor ¼ 5e-9 and was set as a fixed parameter. Panel D: Average simulations of 500 tissues in silico predicting cumulated incidence of breast cancer at a given age (21) . Calibration parameters that led to the lowest mean error square between predicted cancer incidence and epidemiological data for the US are given in Table 1 . Calibration of mutation rate was done for various initial tissue sizes (i.e., 100 3 100, 200 3 100, 200 3 150, 200 3 200), showing that large initial tissue requires a lower mutation rate for the same incidence. 5.6 e-3 Mutation rate l n (stage n ! stage n þ 1) n 3 3.8 e-6 Senescence factor 5 e-9 Tumor growth 1/365 a See Fig. 2A for all values.
impact on cancer incidence was assessed. Our baseline level of senescence that was kept for the rest of the simulations gives around 13% senescence in the whole tissue and 11.2 6 1.31% incidence at age 80. Increasing the final level of senescence to 40% only reduces the incidence of breast cancer to 9.4 6 1.27 %. The effect is more noticeable when senescence hits unrealistic values of 70% and above, leading to breast cancer incidence below 6%.
RESULTS
Targeted Effects (TE)
After calibrating parameters to fit spontaneous cancer incidence from epidemiological data, our model was then used to predict levels of excess breast cancer that one would expect from low-LET exposure. This was done by modifying transient mutation and cell death rates using published data on human cells exposed to low-LET radiation.
The additional radiation-induced death rate was derived from clonogenic data of Lin et al., who studied the response of nonmalignant MCF10A mammary epithelial cells (29) , and dose dependence was simulated using the alpha/beta fit model (Table 2) . However, cells are not expected to die readily after X-ray exposure, as this is not what is observed in cell culture and even less in vivo. Rather, the cells undergo a few cell cycles before dying either through apoptosis, necrosis or mitotic catastrophe. Mitotic catastrophe is not a cell death mechanism per se, but the process by which the cell will lose its reproductive capacity, i.e., after irradiation, some cell lines and cancer cell lines in particular will continue to divide despite harboring DNA damage. These uncontrolled divisions lead to the loss of chromosome material, up to the point that daughter cells are no longer able to divide. The time it takes for a cell to die was therefore modeled in two ways. First, we assumed that death was spread evenly through a 14-day period based on previous work (30) . For example, implementation of this model led to an additional 5.7% of all cells being deleted randomly every day for 14 days after 3 Gy X irradiation (''beta constant'' model; Fig. 3A ) before returning to the normal b value of Fig. 2A . The other death model we used assumed death rates change over time after irradiation with an exponential attenuation as suggested by in vitro work (31, 32) . This was implemented by assuming an exponential decay over 14 days, imposing the same overall amount of death during the 14-day period after irradiation. We tested two conditions: either two or threefold increased death at day 0 compared to the ''beta constant'' model (i.e., ''beta X2'' model has 11% excess death at day 0 and ''beta X3'' model has 17% excess death at day 0 after 3 Gy irradiation). Figure 3B shows the exponential model for ''beta X3''.
In the TSCE model, mutation rates encompass many possible genetic targets to obtain an initiated (l 1 ) or transformed (l 2 ) cell. To predict the impact of radiation perturbation on the TSCE model we needed to propose a model affecting the mutation rate after irradiation. We will assume radiation induces a transient increase of l, which is proportional to dose for 24 h postirradiation. This can be explained as follows.
As we and others have previously shown at great length, mutation rates are a function of radiation dose with larger genes being more likely mutated (33) (34) (35) . In addition, gene location in the nucleus probably plays a role in mutation frequency since damage production and DNA repair are modulated by chromatin territories (36, 37) and therefore individual genetic predisposition is at play here. However, as a first gross approximation, one can argue that initiation and transformation mutation rates are mainly the result of point mutations or small deletions of a large and unknown DNA target and that large deletions induced by two separate DNA double-strand breaks (DSBs) can be neglected since they often lead to cell death due to deletion of vital genes (35) . This greatly simplifies the model by not requiring a quadratic dose term and by assuming mutation rate is increased linearly with dose during exposure. The amplitude of such increase can be approximated using experimental data measuring DNA DSB levels in human cells. According to our previous work and the published literature, baseline damage in peripheral blood lymphocytes range from 0.004 foci/cell in children up to 0.2-1 foci/cell in healthy adult donors when measured either using the c-H2AX assay or (38) (39) (40) (41) . Let us choose the mid-range value (0.5 foci/cell) as a baseline damage level without radiation in a healthy population. Thus, this level of endogenous damage is directly correlated to the spontaneous mutation rate l. Next, low-LET radiation exposure yields approximately 30 DSBs/cell/Gy (42). This gives a 30/0.5 ¼ 60 ratio for foci levels between control cells and cells irradiated by 1 Gy. This dose dependence can be generalized as follows in the TSCE model:
where D is in Gy and l n is increased only for 24 h postirradiation. Such perturbation is shown in Fig 3C for various doses. Radiation perturbations of l and b parameters in the TSCE model were simulated for X-ray doses ranging from 0.05-3 Gy. Note that targeted effects were entirely modeled from experimental in vitro data and they were integrated into the TSCE model, making our simulations true predictions and not fits. The predicted excess relative risk (ERR) was compared to breast cancer ERR in A-bomb survivors (4). Preston et al. computed ERR at age 70 for individuals irradiated at age 30 after the Hiroshima and Nagasaki bombardments. Our simulations were therefore stopped at age 70 to match Preston reference, and the three different death models were tested (death rate constant: ''beta constant'', death rate decreasing exponentially: ''beta 2X'' and ''beta 3X''). Simulations were performed for 10 groups of 50 people. Predicted ERR shown in Fig. 3D indicate that the exponential cell death rate models predict accurately the A-bomb data for large doses (2 and 3 Gy). This is not true for lower doses where predictions are well below the observed ERR. In contrast, the constant cell death model led to underestimation of the reported A-bomb data for any simulated doses, which suggests that additional mechanisms must be considered to explain the observed levels of cancer. We hypothesize in this case that nontargeted effects (NTE) are at play, which are investigated next.
Nontargeted Effects
Nontargeted effects reflect the impact of radiation on modifying cell signaling and the tissue microenvironment after exposure, which leads to systemic changes in entire organs. These have additional impacts from the classic targeted effects (i.e., direct DNA damage and cell death, already simulated in the previous section). We use modeling in this section to evaluate the level of NTE required to FIG. 3 . Model calibration for low-LET-induced breast cancer incidence. Panel A: Death levels are set based on clonogenic data but with death spread evenly over a 14-day period (30) . Panel B: Second death model, assuming the same overall level of death but with death spread after an exponential decay over a 14-day period (31, 32) . In this example, initial death at day 0 is 3 times larger than in the constant model in panel A. We also considered twofold differences. Panel C: Mutation rates are assumed to be increased only for one day after irradiation. For simplification, the rate of mutation is set proportional to the baseline rate found for spontaneous damage based on experimental data using a linear dependence with dose (see Materials and Methods). Legend shows some of the tested doses in Gy. Panel D: Predicted ERR dose dependence of breast cancer at age 70 assuming radiation exposure at age 30. Each solid line represents a set of 500 simulated in silico women, exposed at a given age using TE only scenario. Simulations for various cell death models are compared to A-bomb data (4) (plotted as full circles for age of exposure equal to 30 years old).
explain the lower cancer incidence we predicted in the lowdose range by only considering targeted effects (Fig. 3C) .
Two NTE models were tested: radiation-induced genomic instability (RIGI) and radiation-induced chronic inflammation (RICI). RIGI was implemented by increasing the mutation rate in the entire tissue in a uniform manner for prolonged periods after irradiation (i.e., l GIN ¼ l 3 f GIN ) where l GIN is the new mutation rates in tissue when RIGI is active and f GIN is the radiation-induced multiplicative factor. We used our model to evaluate f GIN and see how it depends on dose by preforming a parameter sweep for RIGI duration and f GIN , leading to an array of simulated ERR. This is shown in Fig. 4A , where predicted ERR for 3 Gy irradiation are shown as a plane. Irradiation was delivered in silico at age 30 and ERR assessed at age 70 to match the conditions used in the cancer breast A-bomb data (4). The intersection of the plane in Fig. 4A with the published ERR value (i.e., 2.2 at 3 Gy) represents all pairs of duration and multiplicative factor f GIN that can lead to the right ERR. Figure 4B shows the resulting iso-ERR curves generated this way for three doses: 0.5, 1 and 3 Gy. One can note that RIGI duration decreases exponentially with the multiplicative factor f GIN for all three doses simulated. The iso-ERR curves for all three doses are closest when f GIN ;17 and RIGI duration is ;97 days (Fig. 4B, dashed lines) . Using these parameters, a new set of simulations predicting Preston ERR can be computed [TE þ RIGI scenario (Fig.  4C)] clearly showing accurate predictions all the way down to 0.2 Gy. Therefore, our model confirms that RIGI is dose independent and is triggered by low-level ionizing radiation. Note that if we use instead the exponential cell death models (beta X2, beta X3), one cannot find a set of values that can predict the ERR for all doses, mainly because it always leads to overestimations for doses .1 Gy (data not shown).
RICI was implemented by increasing the death rate in the entire tissue by a fold increase in a uniform manner for prolonged periods after irradiation. The same approach that was applied for RIGI was done for RICI (data not shown). Duration of 1,825 days and induction fold of 2 were chosen as the best fit. We noted, however, that the TE þ RICI scenario gave less stable results than the TE þ RIGI scenario. This is mainly because there is one more step involved when chronic inflammation is chosen as nontargeted effect. Indeed, cell mortality is tuned at a higher value, which implies more cell division to fill the gap left by the dead cell. Consequently, it also implies a greater possibility for mutations, not because l is higher but because there are more daughter cells that can be targeted. In the case of RIGI, only one process is at play: the mutation rate increases, the death rate and the number of targeted cells remain stable. To keep less variable outcomes in our stochastic model, we chose RIGI as our principal nontargeted effect in the rest of this work, allowing for the number of simulations to be kept at a reasonable-to-reach statistical significance.
Modeling Exposure to Cosmic Radiation
For high-LET exposure, the mutation and death rate from Fig. 3 were adjusted to reflect the change of radiation quality using published RBE. The change in death rate was made on the basis of our previous model predicting RBE for 10% survival in MCF10A cells exposed to high-LET particles using the principle of DSB clustering as the main factor for higher cell death incidence than for low LET (7). Even though MCF10A cells are immortalized, they are nonmalignant and show similar response to primary human breast cells. For example, 10% cell survival of MCF10A is observed after 4 Gy (29) against 4.7 Gy irradiation of primary breast cells (43) . RBE for mutation rate was based on a study that assessed HPRT -mutants in mammalian cells after exposure to a range of high-LET particles (44) . For nontargeted effect, the RIGI scenario was adopted and RBE of 1 was used, as we showed no dose dependence for RIGI in the previous section for low-LET radiation. This is in good agreement with our previous work showing that in human breast cells NTE was not increased with exposure to high-LET radiation (43) . Figure 5A shows RBE prediction for breast cancer induction at age 70 after exposure at the age of 30 to 1 Gy of high-LET particles ranging from 10-1,000 keV/lm, using the low-LET cancer incidence dose dependence to compute the equivalent ERR (Fig. 4C) . The maximum RBE for breast cancer induction peaks at approximately 220 keV/ lm with a value close to 5. For comparison, we used a mutational RBE peaking at 100 keV/lm (44), while survival fraction RBE for breast cells peaked around 400 keV/lm using our previous model (7). This illustrates the relative contribution of both mutational and death events, leading to a competition between RBE peaks. For comparison, we also computed RBE when we only have TE with the exponential cell death model (TE with beta X3), as this led to accurate low-LET ERR for high doses only. As expected, this led to much higher RBE. Finally, to better characterize the contribution of RIGI in RBE, we computed the scenario involving only targeted effects with beta constant. As shown in Fig. 5A , the addition of RIGI at low and very high LET leads to a twofold increase in RBE for breast cancer induction compared to TE alone (TE with beta constant). Another way to visualize the contribution of RIGI is to compute for each simulated LET the additional number of cancers generated in the TE þ RIGI scenario against TE only (using beta constant in both cases). This is shown in Fig. 5B , suggesting that nearly 30% of the excess cancers are due to RIGI at low and very high LET, while only 10% at intermediate LET. This is expected, as RIGI is dose and LET independent. Therefore, when TE is at its maximum (i.e., intermediate LET), RIGI has the lowest contribution. All radiation parameters are summarized in Table 2 .
DISCUSSION
Modeling the complexity of the tissue response to ionizing radiation has been an ongoing challenge because of the heterogeneity of tissue, the large time interval between exposure and cancer detection and the lack of experimental data needed to inform computer models. Thus, deterministic models have dominated the field (8, 10-13) with epidemiologic data from A-bomb survivors remaining the gold standard for risk assessment (4). However, the growing complexity of the data from radiation biology that has been elucidated over the past 20 years needs to be taken into account with the outdated models, and novel approaches bypassing the limitation of epidemiologic approaches have become a necessity for improving risk management.
The old paradigm that biological consequences from radiation exposure arise solely from events occurring at the time of exposure has been challenged in the last two decades by the observation of nontargeted effects such as genomic instability, bystander and nonclonal effects, abscopal effects and delayed cell death (45, 46) . All have in common that they are displaced in time or space from the initial insult and arise as a consequence of intercellular signaling. The argument has been made that radiation is not only the initiating lesion but also promotes the acquisition of secondary genetic changes due to NTE, possibly involving long-term tissue responses to radiation due to oxidative stress and cytokine production (47) . In this work, we chose to concentrate on genomic instability and chronic inflammation for NTE, as they are readily applicable to the cell level used in our in silico tissue. Generally, there is a lack of evidence for a conventional dose-response relationship for RIGI with no increased expression at high doses, and RIGI is modulated by cell type and genetic predisposition (48) .
Persistent subclinical inflammation has been reported in Japanese A-bomb survivors (49) . In the context of chronic inflammation, production of reactive oxygen/nitrogen species by macrophages or neutrophils causes collateral damage in adjacent cells in the form of mutational events. It is thought that this chronic inflammation may confer predisposition to malignancies and has recently been linked to the development of radiation-induced leukemia (42) . In addition, phagocytic uptake of apoptotic cells can result in further apoptosis by the release of soluble signals, triggering Fas-mediated apoptosis in bystander cells (50) . Another study correlated delayed apoptosis with the appearance of neoplastically transformed foci (51) .
Over the years our group has developed approaches that distinguish themselves from the classic deterministic models. Our work has benefited from the use of agentbased models, a stochastic approach simulating life and emerging properties of complex interacting entities (5, 7, 22) . These are well suited for NTE modeling because they allow us to instantaneously simulate and modify information related to spatial structure of a tissue, cell heterogeneity, time scale and cell signaling. Our ABM models have already spanned from disruption of stem cell self-renewal signaling to three-dimensional (3D) breast epithelium reorganization and human breast senescence (6, 22) . Others have also shown the efficiency of such approaches in modeling radiation response (52, 53) .
Here, we have introduced a simplified agent-based model where a cell is represented as a pixel, which cannot move or interact, but can die or divide to neighboring pixels. We refer to this model as an automaton. Removing the need for tracking individual agents allows us to gain computing speed and to lower memory usage for simulations. This was necessary to produce large in silico cohorts of women exposed to a variety of radiation doses and radiation qualities in an attempt to predict cancer risk from exposure to cosmic radiation. We first implemented the two-stage clonal expansion model with automata to simulate tumor incidence arising spontaneously in humans due to random mutations. As we have done in previous models (22) , breast ducts cut along their length can be modeled as simple 2D sheets of one single cell layer. We also assume that initiated cells are still contact inhibited and are still attached to the basement membrane and thus remain within the 2D sheet just like normal cells (6) . On the other hand, proliferation potential and genomic instability are increased in initiated cells in our model. For TSCE, once an initiated cell acquires another set of gene mutations specific to transformation (mutation rate l 2 ), it is classified as a neoplastic cell and its interaction with the basement membrane is compromised allowing it to proliferate inside the lumen (54) . Lumen invasion has been modeled in sophisticated 3D in silico approaches (6, 55, 56) but these later models require large computer frameworks when handling millions of cells and millions of simulations. To keep size and simulation time manageable, we therefore kept the model as a 2D sheet where neoplastic cells invade neighboring cells instead of growing within the lumen in the case of 3D models. We found that detection time was a function of invasion parameters and detectable size programmed within the model and modifying these parameters only change the lag time, not the cancer frequencies. Therefore, using a 3D model would not have changed our conclusions.
After identifying parameters leading to accurate spontaneous rate observed in the female population for breast cancer, we modeled an acute radiation exposure by modifying these parameters based on experimental data. We first modeled targeted effects by modifying mutation rates and cell death rates for a short duration after an acute exposure (day 1 and 14, respectively). Perturbations of the TSCE model led to higher cancer incidence, allowing us to compute an ERR for various doses of low-LET radiation. The predicted ERR were lower than A-bomb breast cancer ERR for doses lower than 2 Gy, suggesting TE alone cannot fully explain radiation-induced carcinogenesis and that NTE are also contributing. The NTE model that best explained the A-bomb data was the induction of a chronic level of genomic instability ;17 times higher than spontaneous levels lasting 97 days after low-LET exposure. Induction of genomic instability was dose independent and thus added for all simulated doses (.0.1Gy). On the other hand, the model could not allow us to draw definitive conclusions about the absolute duration and intensity of RIGI. For instance, a shorter duration could lead to the same outcome if genomic instability was set higher. To put this result into perspective, we can compare the model to experimental observations. For in vitro data, it was shown that RIGI presents the same kind of mutation spectrum as spontaneous mutations and can persist over many cell doublings, i.e., more than 40 divisions in mammary epithelial cells exposed to gamma rays or neutrons (57) . Similarly, in in vivo experiments involving mice, RIGI has been reported to last up to one year after irradiation (58).
Kaiser et al. have also looked at the relative contribution of TE and NTE to fit the A-bomb ERR at 1 Gy using empirical models mixed with a deterministic implementation of TSCE (59) . In their model, they concluded that the age dependence of ERR could be explained by three different modes of actions for radiation: 1. Either direct effect on initiation alone; 2. Long-life increase of proliferation of precancerous cells; or 3. Long-life increase of genomic instability. However, in their model there are no biological parameters derived from experiments and the model does not represent spatial constraints from a tissue in homeostasis. In our case, we directly visualized the impact of various biological mechanisms on carcinogenesis, giving us more biological insights than simply fitting a curve.
Once the NTE model was established for low-LET radiation, we challenged our model to predict breast cancer incidence in an artificial human cohort exposed to various high-LET particles. This was done by simply modifying the TE parameters using published RBE for cell death and mutation. In turn, we predicted RBE for breast cancer induction, which reached a maximum of 5 after exposure with 220 keV/lm. In contrast, RBE were close to 1 for LET .1,000 keV/lm or LET ,10 keV/lm. Note that the LET dependence used for cell death RBE is based on the concept that DNA DSBs are naturally gathered into a common repair center (36, 60) , a paradigm that leads to higher cell death at high dose or higher LET in human breast epithelial cells (7) . One could have used published RBE on other cell lines (61) instead of these theoretical RBEs. Using published RBE instead would still lead to similar cancer RBE since values and dose curve looked very similar. The advantage of using theoretical death RBE based on DSB clustering formalism (7) is that we can predict any dose, dose rate and LET scenario.
To put these RBE predictions into perspective, we should compare them to the most comprehensive data set for tumor induction after high-LET irradiation (2, 62) . LET levels ranging from ;1.5 to 170 keV/lm were investigated in mice, and the measured RBE values for Harderian gland tumor incidence were found to be much higher than in our models, with RBE ;27-40 for 56 Fe. The Harderian gland is not present in humans, and these RBE discrepancies illustrate the ongoing challenge of scaling data from mice to humans. However, one potential explanation is that NTE may account for some of these discrepancies, reflecting the very distinct microenvironment of tissues and species. In particular, Cucinotta et al. derived an analytical model to fit Harderian gland tumor prevalence and showed that NTE had a significant impact by increasing RBE for very-lowand very-high-LET radiation (63) . This result is in agreement with our model in which NTE is triggered for any simulated doses in an equal manner, making it relatively more significant at extreme LET or at low doses (Figs. 4C and 5 ).
CONCLUSION
Currently, our automata model can provide RBE for breast cancer induction with a large panel of particle radiations. Other types of cancers can be implemented in a few steps. First, the calibration for spontaneous cancer induction has to be performed and spontaneous mutation and death rates must be obtained for a specific tissue. Next, the death rate after irradiation must be adapted. This is easily done on the basis of survival fraction for a specific cell line exposed to X rays and using our previous formalism on DSB clustering to predict death rate for high-LET radiation (7). However, a knowledge gap exists regarding RIGI with many remaining questions. For example, is there a dose threshold for RIGI? What is the dependence of RIGI with respect to species and tissues? Is there any dose shape curve for RIGI past the threshold? How does RIGI change in the context of chronic radiation exposure?
Finally, in the context of space missions, and in particular the upcoming Mars missions where it is expected that astronauts will be exposed to more than 1 Sv in the course of a three-year mission, the risks have not yet been sufficiently determined. Space conditions of chronic lowdose, high-LET radiation have presented an ongoing challenge in the modeling of long-term health hazards from space radiation. This may become a reality with our model, as it provides a tool to simulate real space conditions with both LET and time scales being fully compatible for chronic exposure over days or months. We believe in the future that physiological information obtained on astronauts before, during and after a mission could be integrated into our model to better inform long-term effects such as NTE and RIGI and create more accurate risk models.
